Skip to main content
Clinical Trials/EUCTR2015-000730-30-GB
EUCTR2015-000730-30-GB
Active, not recruiting
Not Applicable

A randomised clinical trial comparing endovenous laser ablation and mechanochemical ablation (ClariVein®) in the management of superficial venous insufficiency. - Laser Ablation versus Mechanochemical Ablation (LAMA) trial

Hull and East Yorkshire Hospitals NHS Trust0 sitesApril 14, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Varicose veins (VVs) or Superficial Venous Insufficiency (SVI) of the legs results from inflammation mediated damage to vein structure, allowing reverse flow. SVI affects 30% of adults and is associated with symptoms causing pain and disability
Sponsor
Hull and East Yorkshire Hospitals NHS Trust
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 14, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Hull and East Yorkshire Hospitals NHS Trust

Eligibility Criteria

Inclusion Criteria

  • \- Age 18 or over
  • \- Symptomatic SVI which will likely benefit from treatment in the opinion of an experienced specialist and the participant
  • \- Clinical grades C2\-C6 on the CEAP system
  • \- Superficial axial incompetence with proposed treatment lengths of at least 10cm
  • \- Treatment with either endovenous laser ablation or mechanochemical ablation is technically feasible in the view of an experienced endovenous specialist
  • \- Patient is willing to participate (including acceptance of randomisation to either treatment) and give valid, informed consent in the English language
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 140

Exclusion Criteria

  • \- One of the treatments is thought to be preferable by either the patient or an experienced endovenous specialist
  • \- Unwilling or inability to comply with the requirements for follow\-up visits
  • \- Known allergy to any medications used during treatment
  • \- Known right to left circulatory shunt
  • \- Evidence of acute deep venous thrombosis or complete ipsilateral occlusion
  • \- Pelvic vein insufficiency
  • \- Active or recent thrombophlebitis (within 6 weeks)
  • \- Impalpable foot pulses with Ankle\-Brachial Pressure Index of less than 0\.8
  • \- Pregnancy or breast feeding
  • \- Active malignancy

Outcomes

Primary Outcomes

Not specified

Similar Trials